IFW

Doc

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

MAR O & 2006 W

	Application Number	10/522,319		
TRANSMITTAL	Filing Date	01/25/2005		
FORM	First Named Inventor	Stanley George BONNEY		
	Art Unit	3743		
(to be used for all correspondence after initial filing)	Examiner Name	Teena Kay Mitchell		

Total Number of Pages in This Submission	on	Attorney Docket Number	PG4886-B USW		
	ENCLOSU	RES (Check all that apply	· · · · · · · · · · · · · · · · · · ·		
Fee Transmittal Form	Drawing(s		After Allowance Communication to TC		
Fee Attached	Licensing-	related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Convert to a lack to the convert to a lack to the convert to a lack to the convert to the convert to the convert to a lack to the convert to the c	Proprietary Information		
Affidavits/declaration(s)		Attorney, Revocation Correspondence Address	Status Letter		
Extension of Time Request	Terminal [Disclaimer	Other Enclosure(s) (please identify below):		
Express Abandonment Request	Request fo	or Refund			
Information Disclosure Statement		per of CD(s)			
Certified Copy of Priority Document(s)	Remarks				
Response to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.				
SIGNAT	JRE OF APPLICAN	IT, ATTORNEY, OR AGEN	т		
Firm Name GlaxoSmithKline Signature	863				
Printed name J. Michael Strickla	nd				
Date March 1, 2006		Reg. No.	47,115		
	ERTIFICATE OF	TRANSMISSION/MAIL	NG		
I hereby certify that this correspondence is t	eing facsimile transmi	tted to the USPTO or deposited			
Signature Cohm	ie Jones	······································			
Typed or printed name . Johnie Jones		Date	March 1, 2006		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No.: PG4886-B USW

MAR O 6 2006 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

N RE: Application of Stanley George BONNEY, et al.

Serial No.: 10/522,319

Art Unit: 3743

Filing Date: 01/25/2005

Examiner: Teena Kay Mitchell

For:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[]	Copies of the following references are enclosed. References # 26-54 Copies of the references were submitted in parent application Serial No					
Α.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).					
	OR						
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).					
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.					
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.					
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).					

Docket No.: PG4886-B USW

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.			
	In accor	rdance with the requirements of 37 CFR 1.97(d):			
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]			
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and			
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.			
[X]	-	charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.			

Respectfully Submitted

J. Michael Strickland Attorney of Record Registration No. 47,115

Date: March 1, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9024 Facsimile: (919) 483-7988 **FORM PTO-1449** ATTORNEY DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE STATEMENT JAP 12 **PG4886-B USW** 10/522,319 APPLICANT Stanley George BONNEY, et. al. FILING DATE **GROUP** 01/25/2005 3743 **U.S. PATENT DOCUMENTS** Filing Date xaminer If Appropriate **Issue Date Patent** Name Class Subclass Initials Number 1. 3,269,389 08/30/1966 Meurer et al. 2. 4,627,432 12/09/1986 Newell et al. 3. 4,778,054 10/18/1988 Newell et al. 03/14/1989 4. 4,811,731 Newell et al. 5. 4,940,966 07/10/1990 Pettigrew et al. 6. 5,002,048 03/26/1991 Makiej, Jr. 7. Weinstein et al. 5,007,419 04/16/1991 8. 5,437,267 08/01/1995 Weinstein et al. 08/01/1995 9. 5,437,270 Braithwaite Keller 10. 5,462,205 10/31/1995 5,497,765 03/12/1996 Praud et al. 11. 12. 5,505,704 04/09/1996 Pawelka et al. 13. 5,524,613 06/11/1996 Smedley et al. 14. 5,590,645 01/07/1997 Davies et al. 15. 5,664,557 09/09/1997 Makiej, Jr. Continue on page FOREIGN PATENT DOCUMENTS Translation Document Publication Yes | No Number Date Country Class Subclass 26. 1461280 02/27/1969 DΕ X 27. 03/19/1975 1387954 GB 28. 0372777 06/13/1990 EP 09/25/1991 2242134 29. GB EP 30. 0469814 02/05/1992 31. 92/12402 07/23/1992 PCT 32. 0521434 01/07/1993 EP Х 33. 4305277 08/25/1994 DE 34. 96/31790 10/10/1996 PCT 35. 98/30332 07/16/1998 **PCT** 36. 98/34664 08/13/1998 **PCT** 37. 98/51257 11/19/1998 PCT 38. 2327408 01/27/1999 GB 39. 08/12/1999 PCT 99/39991 40. 00/00411 01/06/2000 **PCT** 41. 00/45879 08/10/2000 **PCT** 42. PCT 00/64519 11/02/2000 00/64520 43. 11/02/2000 PCT Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Continue on page

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED

EXAMINER

FORM PTO-1449			ATTORNEY DOCKET NO. SERIAL NO.					
INFORMATION DISCLOSURE STATEMENT					PG4886-B USW			
				APPLICANT	6414	-1		
					BONNEY, Geo			
					FILING DATE	L	GROUP	
			U.S. P	ATENT DO	OCUMENTS	· · · · · · · · · · · · · · · · · · ·	<u> </u>	
								Filing Date
Examiner		Patent	Issue Date		Name	Class	Subclass	If Appropriate
Initials		Number						
	16.	5,772,085	06/30/1998	Bryant et a	al.			
	17.	5,830,490	11/03/1998	Weinstein	et al.			
	18.	5,860,419	01/19/1999	Davies et	al.			
	19.	5,873,360	02/23/1999	Davies et al.				
	20.	5,901,883	05/11/1999	Ritsche				
	21.	5,941,241	08/24/1999	Weinstein et al.				
	22.	6,029,663	02/29/2000	Eisele et a	ıl.			
	23.	6,116,237	09/21/2000	Schultz et				
	24.	2001/0027789	10/11/2001	Goede et a				
	25.	2004/0050864	03/18/2004	Stradella				
			C	ontinue on p	page	L		
					CUMENTS (Co	nt'd)		
		Document	Publication		(33	T T		Translation
		Number	Date	(Country	Class	Subclass	Yes No
	44.	01/17595	03/15/2001	PCT				<u> </u>
	45.	01/26020	04/12/2001	PCT		<u> </u>		
	46.	01/26021	04/12/2001	PCT				
	47.	01/31578	05/03/2001	PCT				
	48.	01/39823	06/07/2001	PCT		†		
	49.	01/41849	06/14/2001	PCT				
	50.	01/68169	09/20/2001	PCT				
	51.	01/98176	12/27/2001	PCT				
	52.	02/05879	01/24/2002	PCT				
	53.	1300171	04/09/2003	EP				
1	54.	03/061744	07/31/2003	PCT		<u> </u>		
			0.70.0200					
							.,	
			· · · · · · · · · · · · · · · · · · ·					
		<u> </u>	C	ontinue on p	page			
		OTHER DOCUM				ate. Page Num	ber, Etc.)	
				,		, g	,,	- **
						· .	• • • • • • • • • • • • • • • • • • • •	
		-					· · · · · · · · · · · · · · · · · · ·	
		<u>. </u>		Continue on	nage			
EXAMINER				Chimac on	<u> </u>	DATE	CONSIDERE	D
						2		-
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								